The development of monoclonal antibody therapy in leukemias

Hybridoma

Volumn 20, Issue 3, 2001, Pages 145-148

  Syrigos, K N ^a   Pliarchopoulou, K ^a   Harrington, K J ^a  

^a SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ALPHA INTERFERON; CAMPATH 1G; CAMPATH 1M; CD20 ANTIGEN; CD33 ANTIGEN; CD45 ANTIGEN; CD52 ANTIGEN; CHLORODEOXYADENOSINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTOKINE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; INTERLEUKIN 6; LACTATE DEHYDROGENASE; LIVER ENZYME; MONOCLONAL ANTIBODY; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIGEN BINDING; ARTICLE; B CELL LEUKEMIA; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; HAIRY CELL LEUKEMIA; HUMAN; LEUKEMIA CELL; LYMPHOCYTE COUNT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; REMISSION;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOTHERAPY; LEUKEMIA;

EID: 0034825963     PISSN: 0272457X     EISSN: None     Source Type: Journal    
DOI: 10.1089/027245701750293466     Document Type: Article

References (25)

1. Antibody-targeted therapy for myeloid leukemia
2. Monoclonal antibody M195: A diagnostic marker for acute myelogenous leukemia
3. Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195
4. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies
5. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: A novel and potent family of antitumor antibiotics
6. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype
7. Ex vivo depletion of T cells from bone marrow grafts with CAMPATH-1 in acute leukemia: Graft-versus-host disease and graft-versus-leukemia effect
8. CAMPATH-1 monoclonal antibodies in bone marrow transplantation
9. Treatment of acute leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed
10. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia
11. A phase II trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: Specific targeting without immunogenicity
12. Molecular remission induction without relapse after anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia (APL)
13. Interim analysis of the efficacy safety of CMA-676 in patients with AML in first relapse
14. Selective ablation of acute myeloid leukemia using an anti-CD33 calichaemicin immunoconjugate
15. Comparison of the efficacy and safety of Gemtuzumab Ozogamicin (CMA-676) in patients <60 and >60 years
16. Short-term outcomes after treatment for relapsed AML: A comparison of recent CMA-676 clinical trial data and historical control data
17. Achievements, failings and promises of radioimmunotherapy
18. Radioimmunotherapy: Recent results and future directions
19. Use of monoclonal antibodies for the diagnosis and treatment of bladder cancer
20. Targeted alpha-particle therapy for myeloid leukemias: A phase I trial of Bi-21-HuM195 (anti-CD33)
21. Radioimmunotherapy of ovarian cancer
22. Successful treatment and retreatment of resistant B-cell chronic lymphocytic leukemia with the monoclonal anti-CD20 antibody rituximab
23. Chimeric monoclonal anti-CD20 antibody (rituximab) - An effective treatment for a patient with relapsing hairy cell leukemia
24. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)
25. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: Association with increased infusion-related side effects and rapid blood tumor clearance